QC
BDTX icon

Quadrature Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Quadrature Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
76,706
+39,232
+105% +$96K ﹤0.01% 1425
2026
Q1 		$79.8K Buy
+37,474
New +$89.1K ﹤0.01% 1252
2025
Q4 		– Sell
-11,366
Closed -$43.1K – 1265
2025
Q3 		$43.1K Buy
+11,366
New +$33.2K ﹤0.01% 964

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Quadrature Capital's BDTX Position: Q2 2026 in Review

Quadrature Capital increased its Black Diamond Therapeutics (BDTX) stake by 105% in Q2 2026, buying an estimated $96K and bringing the position to 76,706 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

Quadrature Capital first reported a position in BDTX in Q3 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Quadrature Capital held 76,706 shares of Black Diamond Therapeutics worth $142K as of Q2 2026.
  • Quadrature Capital bought 39,232 Black Diamond Therapeutics shares in Q2 2026, an estimated $96K.
  • Black Diamond Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1425 holding.
  • Quadrature Capital first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.